American Journal of Cancer

, Volume 3, Issue 2, pp 119–131 | Cite as

Therapeutic Options in Hepatocellular Carcinoma

Review Article

Abstract

Hepatocellular carcinoma (HCC) is common in Africa as well as south eastern Asia, and is usually related to chronic hepatitis B virus infection although chronic hepatitis C virus infection and alcohol abuse also play a major role. Mass vaccination against the hepatitis B virus in neonates has been undertaken in Taiwan and South Africa with encouraging results.

The treatment of choice for HCC is surgery, but radical resection is only feasible in a small percentage of patients because of the advanced nature of the disease and underlying liver cirrhosis. If surgical resection is not feasible, intra-arterial chemoembolization may reduce the size of tumors providing good palliation, and possibly render inoperable tumors operable. Locally ablative therapies including percutaneous ethanol injection, cryosurgery, microwave coagulation, and radiofrequency thermal ablation are useful in patients with limited disease, but are methods that are only feasible in highly specialized units. Liver transplantation, which is also only available in highly specialized centers, has unfortunately been disappointing. Unresectable HCC has a very poor prognosis, as the disease is highly refractory to most chemotherapy agents, possibly as a result of overexpression of the multidrug resistance gene, mdr1. Overall response rates of 10–15% have been reported with most chemotherapeutic agents, with doxorubicin probably being the most active agent. Other agents studied include fluorouracil as well as the newer oral fluoropyrimidines, etoposide, gemcitabine, anthracycline analogues including mitoxantrone, epirubicin, and pegylated liposomal doxorubicin, as well as cisplatin and the direct thymidylate synthase inhibitors raltitrexed and nolatrexed. Other agents including tamoxifen, tyrosine kinase inhibitors, thalidomide, interferons, and clofazimine have also been studied. Administration of viral vectors containing the p53 gene, or other tumor suppressor and suicide genes, is also a possible future therapy.

Unfortunately as current approaches still remain unsatisfactory, especially in patients with advanced unresectable disease, newly diagnosed patients should, whenever available, be entered onto clinical studies with new agents which may result in better therapies for this highly refractory disease.

Keywords

Gemcitabine Liposomal Doxorubicin Lanreotide Percutaneous Ethanol Injection Raltitrexed 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents. Vol V. Lyons, France: IARC Sci Publ 1989, 88Google Scholar
  2. 2.
    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19(3): 271–85PubMedCrossRefGoogle Scholar
  3. 3.
    Munoz N, Bosch FX. Epidemiology of hepatocellular carcinoma. In: Okuda K, Ishak KA, editors. Neoplasms of the liver. New York: Springer-Verlag, 1987Google Scholar
  4. 4.
    Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol 2001; 12(2): 161–72PubMedCrossRefGoogle Scholar
  5. 5.
    London WT. Hepatocellular carcinoma: etiology and pathogenesis. In: Perry MC, editor. Am Soc Clin Oncol Educational Book. Alexandria (VA): Am Soc Clin Oncol, 1998: 175Google Scholar
  6. 6.
    Okuda K, Obata H, Nakajima Y, et al. Prognosis of primary hepatocellular carcinoma. Hepatology 1984; 4Suppl. 1: 3S–6SPubMedCrossRefGoogle Scholar
  7. 7.
    Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001; 28(5): 441–9PubMedCrossRefGoogle Scholar
  8. 8.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340(10): 745–50PubMedCrossRefGoogle Scholar
  9. 9.
    Venook AP. Management of hepatocellular carcinoma. In Perry MC, editor. Am Soc Clin Oncol Educational Book. Alexandria (VA): Am Soc Clin Oncol, 1998: 176–9Google Scholar
  10. 10.
    Saito T, Shinzawa H, Kuboki M, et al. A randomised controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89(5): 681–6PubMedGoogle Scholar
  11. 11.
    Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus cirrhosis: a randomised controlled trial of interferon-α 2b versus no treatment. Hepatology 1999; 29(6): 1870–5PubMedCrossRefGoogle Scholar
  12. 12.
    Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin Bl by olpitraz in residents of Qidong, PRC. J Natl Cancer Inst 1999; 91(4): 347–54PubMedCrossRefGoogle Scholar
  13. 13.
    Little SA, Fong Y. Hepatocellular carcinoma: current surgical management. Semin Oncol 2001; 28(5): 474–86PubMedCrossRefGoogle Scholar
  14. 14.
    Franco D, Usatoff V. Resection of hepatocellular carcinoma. Hepatogastroenterology 2001; 48(37): 33–6PubMedGoogle Scholar
  15. 15.
    Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia (PA): Saunders, 1964: 50–62Google Scholar
  16. 16.
    Pugh R, Murray-Lyom IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646–9PubMedCrossRefGoogle Scholar
  17. 17.
    Poon RT, Fan ST, Lo CM, et al. Long term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18(5): 1094–101PubMedGoogle Scholar
  18. 18.
    Okuda K, Liver Study Group of Japan. Primary liver cancer in Japan. Cancer 1980; 71(1): 19–25Google Scholar
  19. 19.
    Lai ECS, Ng IOL, You KT, et al. Hepatic resection for small hepatocellular carcinoma: the Queen Mary Hospital experience. World J Surg 1991; 15(5): 654–9PubMedCrossRefGoogle Scholar
  20. 20.
    Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996; 131(1): 71–6PubMedCrossRefGoogle Scholar
  21. 21.
    Takenaka K, Shimada M, Higashi H, et al. Liver resection for hepatocellular carcinoma in the elderly. Arch Surg 1994; 129(8): 846–50PubMedCrossRefGoogle Scholar
  22. 22.
    Jones SM, Roh MS. Results of surgical resection for hepatocellular carcinoma. Cancer Treat Res 2001; 109: 59–75PubMedGoogle Scholar
  23. 23.
    Pal S, Pande GK. Current status of surgery and transplantation in the management of hepatocellular carcinoma: an overview. J Hepatobiliary Pancreat Surg 2001; 8(4): 323–36PubMedCrossRefGoogle Scholar
  24. 24.
    Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by the acyclic retinoid, polyphrenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334(24): 1561–7PubMedCrossRefGoogle Scholar
  25. 25.
    Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a randomised trial. Lancet 1999; 353(9155): 797–801PubMedCrossRefGoogle Scholar
  26. 26.
    Ono T, Yamanoi A, Nazmy El Assal O, et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91(12): 2378–85PubMedCrossRefGoogle Scholar
  27. 27.
    Takayama T, Makuuchi M. Prevention of hepatocellular carcinoma recurrence: actuality and perspectives. Hepatogastroenterology 2002; 49(43): 87–90PubMedGoogle Scholar
  28. 28.
    Peng BG, Liu SQ, Kuang M, et al. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 2002; 93(4): 363–8PubMedCrossRefGoogle Scholar
  29. 29.
    Kashef E, Roberts JP. Transplantation for hepatocellular carcinoma. Semin Oncol 2001; 28(5): 497–502PubMedCrossRefGoogle Scholar
  30. 30.
    Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30(6): 1434–40PubMedCrossRefGoogle Scholar
  31. 31.
    Roayaie S, Frischer JS, Emre SH, et al. Long term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235(4): 533–9PubMedCrossRefGoogle Scholar
  32. 32.
    Suchiro T, Terashi T, Shiotani S, et al. Liver transplantation for hepatocellular carcinoma. Surgery 2002; 131(1 Suppl.): S190–4Google Scholar
  33. 33.
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5): 1164–71PubMedCrossRefGoogle Scholar
  34. 34.
    Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27(6): 1578–83PubMedCrossRefGoogle Scholar
  35. 35.
    Sullivan KL. Hepatic artery chemoembolization. Semin Oncol 2002; 29(2): 145–51PubMedCrossRefGoogle Scholar
  36. 36.
    Carr BI. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 2002; 49(43): 79–86PubMedGoogle Scholar
  37. 37.
    Achenbach T, Seifert JK, Pitton MB, et al. Chemoembolization for primary liver cancer. Eur J Surg Oncol 2002; 28(1): 37–41PubMedCrossRefGoogle Scholar
  38. 38.
    Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94(6): 1747–52PubMedCrossRefGoogle Scholar
  39. 39.
    Barnett Jr CC, Curley SA. Ablative techniques for hepatocellular carcinoma. Semin Oncol 2001; 28(5): 487–96PubMedCrossRefGoogle Scholar
  40. 40.
    Georgiades CS, Ramsey DE, Solomon S, et al. New nonsurgical therapies in the treatment of hepatocellular carcinoma. Tech Vase Interv Radiol 2001; 4(3): 193–9CrossRefGoogle Scholar
  41. 41.
    Pompili M, Rapaccini GL, Covino M, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection. Cancer 2001; 92(1): 126–35PubMedCrossRefGoogle Scholar
  42. 42.
    Huo TI, Huang YH, Wu JC, et al. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as salvage therapy. Scand J Gastroenterol 2002; 37(3): 350–5PubMedCrossRefGoogle Scholar
  43. 43.
    Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterlogy 2002; 49(43): 62–71Google Scholar
  44. 44.
    Kiba T, Numata K, Kitamura T, et al. Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastases. Hepatogastroenterology 2001; 48(38): 427–31PubMedGoogle Scholar
  45. 45.
    Lu MD, Chen JW, Xie XY, et al. Hepatocellular carcinoma: ultrasound guided percutaneous microwave coagulation. Radiology 2001; 221(1): 167–72PubMedCrossRefGoogle Scholar
  46. 46.
    Ishikawa M, Ikeyama S, Sasaki K, et al. Intraoperative microwave coagulationtherapy for large hepatic tumors. J Hepatobiliary Pancreat Surg 2000; 7(6): 587–91PubMedCrossRefGoogle Scholar
  47. 47.
    Olschewski M, Lencioni R, Allgaier H-P, et al. A randomized comparison of radiofrequency thermal ablation and percutaneous ethanol injection for the treatment of small hepatocellular carcinoma [abstract no. 500]. Proc Am Soc Clin Oncol 2001; 20: 126aGoogle Scholar
  48. 48.
    Shiina S, Teratani T, Obi S, et al. Nonsurgical treatment of hepatocellular carcinoma: from PEIT and PMCT to RFA. Oncology 2002; 62Suppl. 1: 64–8PubMedCrossRefGoogle Scholar
  49. 49.
    Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223(2): 331–7PubMedCrossRefGoogle Scholar
  50. 50.
    Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001; 28(5): 503–13PubMedCrossRefGoogle Scholar
  51. 51.
    Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomised trial. Cancer 1988; 62(3): 479–83PubMedCrossRefGoogle Scholar
  52. 52.
    Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma: a comparison of VP16 with adriamycin. Cancer 1983; 51(2): 206–10PubMedCrossRefGoogle Scholar
  53. 53.
    Falkson G, Coetzer BJ. Phase II studies of mitoxantrone in patients with primary liver cancer. Invest New Drugs 1985; 3(2): 187–9PubMedCrossRefGoogle Scholar
  54. 54.
    Hochster HS, Green MD, Speyer J, et al. 4′Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985; 3(11): 1535–40PubMedGoogle Scholar
  55. 55.
    Melia WM, Westaby D, Williams R. Diaminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 1981; 7(4): 275–80PubMedGoogle Scholar
  56. 56.
    Rougier P, Ducreux M, Kerr D, et al. A phase II study of raltitrexed (Tomudex) in patients with hepatocellular carcinoma. Ann Oncol 1997; 8(5): 500–2PubMedCrossRefGoogle Scholar
  57. 57.
    Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8(2): 117–36PubMedCrossRefGoogle Scholar
  58. 58.
    Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S319–28PubMedCrossRefGoogle Scholar
  59. 59.
    Friedman MA. Primary hepatocellular cancer: present results and future prospects. Int J Radiat Oncol Biol Phys 1983; 9(12): 1841–50PubMedCrossRefGoogle Scholar
  60. 60.
    Llovet JM, Ruff P, Tassopoulos N, et al. A phase II trial of oral eniluracil/ 5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001; 37(11): 1352–8PubMedCrossRefGoogle Scholar
  61. 61.
    Pazdur R. New agents for colorectal cancers: oral fluorinated pyrimidines and oxaliplatin. In Perry MC, editor. Am Soc Clin Oncol Educational Book. Alexandria (VA): Am Soc Clin Oncol, 1998: 310Google Scholar
  62. 62.
    Calvert H. Clinical developments with folate-based thymidylate synthase inhibitors. In Perry MC, editor. Am Soc Clin Oncol Educational Book. Alexandria (VA): Am Soc Clin Oncol, 1998: 299Google Scholar
  63. 63.
    Mori K, Hasegawa M, Nishida M, et al. Expression levels of thymidine phosphoylase and dihydropyrimidine dehydrogenase in various human tissues. Int J Oncol 2000; 17(1): 33–8PubMedGoogle Scholar
  64. 64.
    Lozano RD, Part TZ, Hassan MM, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers [abstract no. 1025]. Proc Am Soc Clin Oncol 2000; 19: 264aGoogle Scholar
  65. 65.
    Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric coated tegafur/uracil for advanced stage IVA hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16(4): 452–9PubMedCrossRefGoogle Scholar
  66. 66.
    Leung TWT, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28(5): 514–20PubMedCrossRefGoogle Scholar
  67. 67.
    Zuna PJ, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47(5): 359–65PubMedCrossRefGoogle Scholar
  68. 68.
    Dunk A, Scott SC, Johnson PJ, et al. Mitoxantrone as single agent chemotherapy in hepatocellular carcinoma: a phase II trial. J Hepatol 1985; 1(4): 395–404PubMedCrossRefGoogle Scholar
  69. 69.
    Ruff P, Moodley SD, Rapoport BL, et al. Long term follow-up of pegylated liposomal doxorubicin: a well tolerated and effective agent in advanced inoperable hepatocellular carcinoma [abstract no. 667]. Proc Am Soc Clin Oncol 2001; 20: 168aGoogle Scholar
  70. 70.
    Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11(1): 113–4PubMedCrossRefGoogle Scholar
  71. 71.
    Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma [abstract no. 1054]. Proc Am Soc Clin Oncol 2000; 19: 270aGoogle Scholar
  72. 72.
    Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001; 60(4): 313–5PubMedCrossRefGoogle Scholar
  73. 73.
    Yang T-S, Wang C-H, Hsieh R-K, et al. A 2-stage phase II study of gemcitabine and doxorubicin in patients with advanced hepatocellular carcinoma [abstract no. 670]. Proc Am Soc Clin Oncol 2001; 20: 168aGoogle Scholar
  74. 74.
    Leung TWT, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy in inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5(7): 1676–81PubMedGoogle Scholar
  75. 75.
    Ruff P, Chasen MR, Long JEH, et al. A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ann Oncol 1998; 9(2): 217–9PubMedCrossRefGoogle Scholar
  76. 76.
    van Rensburg CEJ, van Staden AM, Anderson R. The riminophenazine agents clofazimine and B669 inhibit proliferation of cancer cell lines in vitro by phospholipase A2 mediated oxidative and non-oxidative mechanisms. Cancer Res 1993; 53(2): 318–23PubMedGoogle Scholar
  77. 77.
    van Rensburg CEJ, de Bruyn EE, Anderson R. The antiproliferative riminophenazine agents clofazimine and B669 promote lysophospholipid mediated inhibition of Na+, K+ adenosine triphosphate activity in cancer cell lines in vitro. Int J Oncol 1994; 14(4): 1115–9Google Scholar
  78. 78.
    van Rensburg CEJ, Durandt C, Galinski PJ, et al. Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and B669 in tumour bearing rats and mice. Int J Oncol 1993; 3(4): 1011–3Google Scholar
  79. 79.
    Patt YZ, Yoffe B, Charnsangavej C, et al. Low serum α-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5FU and interferon-α-2b. Cancer 1993; 72(9): 2574–82PubMedCrossRefGoogle Scholar
  80. 80.
    Patt YZ, Lozano R, Hassan M, et al. Continuous intravenous infusion of 5-fluorouracil and subcutaneous recombinant interferon-α-2b is an active regimen in hepatocellular carcinoma [abstractno. 671]. Proc Am Soc Clin Oncol 2001; 20: 168aGoogle Scholar
  81. 81.
    Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31(1): 54–8PubMedCrossRefGoogle Scholar
  82. 82.
    CLIP Group (Cancer of Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial Lancet 1998; 352(9130): 819–20Google Scholar
  83. 83.
    Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5 year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002; 8(11): 1013–9PubMedCrossRefGoogle Scholar
  84. 84.
    Raderer M, Hejna MH, Kurataran A, et al. Successful treatment of an advanced hepatocellular carcinoma with the long acting somatostatin analog lanreotide. Am J Gastroenterol 1999; 94(1): 278–9PubMedCrossRefGoogle Scholar
  85. 85.
    Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular carcinoma with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16(6): 1197–201PubMedGoogle Scholar
  86. 86.
    Suzuki H, Seto K, Shinoda Y, et al. Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed HepG2 cells. Am J Physiol 1999; 276(1): G92–7PubMedGoogle Scholar
  87. 87.
    Kin M, Torimura T, Ueno T, et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000 Feb; 16(2): 375–82PubMedGoogle Scholar
  88. 88.
    Eng C, Kindler HL, Stadler WM, et al. SU5416 in advanced colorectal cancer (CRC): a University of Chicago Phase II Consortium Study [abstract no. 2215]. Proc Am Soc Clin Oncol 2001; 20: 116bGoogle Scholar
  89. 89.
    Gajewski TF, Flickinger S, Heimann R, et al. Phase II sudy of anti-angiogenic flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results [abstractno. 1436]. Proc Am Soc Clin Oncol 2001; 20: 360aGoogle Scholar
  90. 90.
    Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral EGFR tyrosine kinase inhibitor, in combination with carboplatin and paclitaxel in previously untreated NSCLC [abstract no. 1301]. Proc Am Soc Clin Oncol 2001; 20: 326aGoogle Scholar
  91. 91.
    Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the EGFR tyrosine kinase inhibitor OSI-774, following platinum based chemotherapy in patients with advanced EGFR expressing NSCLC [abstract no. 1235]. Proc Am Soc Clin Oncol 2001; 20: 310aGoogle Scholar
  92. 92.
    Hammond LA, Figueroa J, Schwartzberg L, et al. Feasibility and pharmacokinetic trial of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer [abstract no. 544]. Proc Am Soc Clin Oncol 2001; 20: 137aGoogle Scholar
  93. 93.
    Yang EB, Wang DF, Mack P, et al. Genistein, a tyrosine kinase inhibitor, reduces EGF-induced EGF receptor internalization and degradation in human hepatoma HepG2 cells. Biochem Biophys Res Commun 1996; 224(2): 309–17PubMedCrossRefGoogle Scholar
  94. 94.
    Mohr L, Geissler M, Blum HE. Gene therapy for malignant liver disease. Expert Opin Biol Ther 2002; 2(2): 163–75PubMedCrossRefGoogle Scholar
  95. 95.
    Ruiz J, Mazzolini G, Sangro B, et al. Gene therapy of hepatocellular carcinoma. Dig Dis 2001; 19(4): 324–32PubMedCrossRefGoogle Scholar
  96. 96.
    Shiba H, Okamoto T, Futagawa Y, et al. Efficient cancer selective gene transfer to hepatocellular carcinoma cells in a rat model using adenovirus vector with iodized oil [abstract no. 1039]. Proc Am Soc Clin Oncol 2001; 20: 260aGoogle Scholar
  97. 97.
    Sangro B, Qian C, Schmitz V, et al. Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann N Y Acad Sci 2002; 963: 6–12PubMedCrossRefGoogle Scholar
  98. 98.
    Wang D, Yang EB, Lek LH, et al. Transmodulation of EGF receptor by interferongamma in human hepatocellular carcinoma HepG2 cells. In Vivo 1997; 11(2): 141–6PubMedGoogle Scholar
  99. 99.
    Wang Z, Qiu SJ, Ye SL, et al. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther 2001; 8(10): 751–8PubMedCrossRefGoogle Scholar
  100. 100.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319(9): 525–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Division of Medical Oncology, Department of Medicine, Faculty of Health SciencesUniversity of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations